Vesugen
Research OnlyAlso known as: KED-vascular, Lys-Glu-Asp (vascular), Vascular tripeptide
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support vascular health by modulating endothelial gene expression. Russian studies suggest cardiovascular protective effects. No Western clinical validation or regulatory approval anywhere.
Research Statistics
Russian bioregulator (Khavinson lab); synthetic vascular tripeptide. Some human observational data from Russian vascular studies. No independent Western clinical trials. Vascular bioregulation mechanism proposed but lacks Western validation.
Research Dossier
Overview
What is Vesugen and what does the research say?
Mechanism of Action
The proposed mechanisms of Vesugen are based entirely on Russian research from the St. Petersburg Institute of Bioregulation and Gerontology. No independent Western validation exists.
How It Works (Simplified)
Vesugen targets vascular health through endothelial gene modulation and related pathways:
Binds to DNA sequences in endothelial cells, modulating expression of genes related to vascular tone, permeability, and cell function.
May influence nitric oxide signaling and endothelial-dependent vasodilation, supporting healthy blood flow and vascular reactivity.
Proposed to reduce oxidative stress in vascular tissue, protecting endothelial cells from age-related damage and dysfunction.
Claimed to counteract age-related changes in vascular gene expression patterns, potentially supporting healthier vascular aging.
Scientific Pathways
Endothelial Gene Modulation Pathway (Vascular Function)
Vesugen → DNA Binding in Endothelial Cells → Gene Transcription Modulation
↓
Vascular Tone Genes ↑ → Endothelial Function Support
↓
Vasodilation Factors → Blood Flow RegulationVascular Protection Pathway (Oxidative Defense)
Vesugen → Endothelial Cell Uptake → Antioxidant Gene Expression ↑
↓
Reduced Oxidative Stress → Endothelial ProtectionKey Context: All research originates from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson’s institute). No independent Western validation exists for any claimed mechanisms.
Important Limitations
- 100% of research from Russian institutes associated with Khavinson
- No independent Western replication of any findings
- No controlled human clinical trials exist
- One small uncontrolled observational study in elderly patients
- Human pharmacokinetics, bioavailability, and optimal dosing unknown
- Translation from cell culture to meaningful cardiovascular benefits is unconfirmed
- Regulatory status: Not approved anywhere; unregulated research peptide
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: Initial effects on endothelial gene expression may begin. Cell culture studies show changes in vascular-related gene markers within days of treatment.
Continued treatment in animal models shows progressive effects on vascular parameters. Endothelial function improvements may develop. Russian protocols typically involve 10-20 day treatment cycles.
Animal studies report measurable improvements in vascular reactivity with extended treatment. Oxidative stress markers may decrease. Effects in humans are uncharacterized.
Long-term effects are based on Russian observational studies in elderly patients. Optimal treatment duration and cycling protocols are not established. Human pharmacokinetics are unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Vesugen product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Vesugen with other peptides. Based on published research and mechanistic considerations.
Cardiogen
CompatibleBoth Khavinson cardiovascular peptides - Cardiogen targets heart muscle, Vesugen targets blood vessel endothelium. May have complementary vascular system effects.
Epithalon
CompatibleBoth Russian bioregulator peptides with different targets - epithalon for telomerase/longevity, Vesugen for vascular health. No known direct interactions.
Vilon
CompatibleBoth short Khavinson peptides - Vilon for immune modulation, Vesugen for vascular support. Different organ targets, potentially complementary.
Thymalin
CompatibleBoth developed within Russian peptide bioregulation research - Thymalin for thymus/immunity, Vesugen for vascular endothelium. No known contraindications.
BPC-157
CompatibleDifferent vascular mechanisms - BPC-157 promotes angiogenesis and tissue healing, Vesugen targets endothelial gene expression. Potentially complementary for vascular health.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Vesugen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.
Livagen
KED, Lys-Glu-Asp, Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.